Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
107 hedge funds and large institutions have $316M invested in Accelerate Diagnostics in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 35 increasing their positions, 31 reducing their positions, and 22 closing their positions.
25% more call options, than puts
Call options by funds: $9M | Put options by funds: $7.2M
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less funds holding
Funds holding: 119 → 107 (-12)
48% less capital invested
Capital invested by funds: $612M → $316M (-$297M)
55% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.21M |
| 2 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$4.15M |
| 3 |
BAMCO Inc
New York
|
+$3.85M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$3.67M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
+$3.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.43M |
| 2 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$3.79M |
| 3 |
William Blair & Company
Chicago,
Illinois
|
-$3.54M |
| 4 |
CC
Chicago Capital
Chicago,
Illinois
|
-$3.05M |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$1.72M |
AXDX Hedge Fund Activity: Q4 2018 in Review
107 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2018, worth a combined $316M — down 48% from $612M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AXDX and 10 opened new positions — a net loss of 12 holders — while 31 trimmed existing stakes and 35 added.
The largest buyer was Credit Suisse, adding an estimated $4.21M. The largest seller was Susquehanna International Group, cutting an estimated $4.43M.
- 107 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2018, down from 119 in Q3 2018.
- Funds reported $316M of Accelerate Diagnostics stock for Q4 2018, down 48% quarter-over-quarter.
- 10 funds opened new Accelerate Diagnostics positions in Q4 2018 and 22 closed out, a net change of -12 holders.
- The largest Accelerate Diagnostics buyer in Q4 2018 was Credit Suisse, an estimated $4.21M added.
- The largest Accelerate Diagnostics seller in Q4 2018 was Susquehanna International Group, an estimated $4.43M sold.
Based on aggregated 13F filings for Q4 2018.